Article
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Diabetes care - 1 Oct 2010
Bailey Swneke D, Xie Changchun, Do Ron, Montpetit Alexandre, Diaz Rafael, Mohan Viswanathan, Keavney Bernard, Yusuf Salim, Gerstein Hertzel C, Engert James C, Anand Sonia
Abstract excerpt
OBJECTIVE: Thiazolidinediones are used to treat type 2 diabetes. Their use has been associated with peripheral edema and congestive heart failure-outcomes that may have a genetic etiology. RESEARCH DESIGN AND METHODS: We genotyped 4,197 participants of the multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial with a 50k single nucleotide polymorphisms (SNP) array,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.